

## FIRST TIME GENERIC APPROVAL

<b>Brand Name</b>	Celontin®
<b>Generic Name</b>	methsuximide
<b>Drug Manufacturer</b>	Novitium Pharma LLC

### New Drug Approval

#### TYPE OF CLINICAL UPDATE

First Time Generic

#### FDA APPROVAL DATE

May 1, 2023

#### LAUNCH DATE

May 5, 2023

#### REVIEW DESIGNATION

Standard

#### TYPE OF REVIEW

Abbreviated New Drug Application (ANDA): 217213

#### DISPENSING RESTRICTIONS

N/A

### Overview

#### INDICATION FOR USE

Methsuximide is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.

#### MECHANISMS OF ACTION

Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

#### DOSE FORM AND STRENGTH

300 mg capsule

#### DOSE & ADMINISTRATION

Optimum dosage must be determined by trial. A suggested dosage schedule is 300 mg per day for the first week. If required, dosage may be increased thereafter at weekly intervals by 300 mg per day for the three weeks following a daily dosage of 1.2 g. Because therapeutic effect and tolerance vary among patients, therapy with methsuximide must be individualized according to the response of each patient. Optimal dosage is that amount of methsuximide which is barely sufficient to control seizures so that side effects may be kept to a minimum.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

## FIRST TIME GENERIC APPROVAL

Methsuximide may be administered in combination with other anticonvulsants when other forms of epilepsy coexist with absence (petit mal).